Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Advanced/recurrence NSCLC patients who have had one or more chemotherapy regimens.
Patients who are to be treated with gefitinib or chemotherapy
Cohort: All advanced/recurrence NSCLC patients participating in this post-marketing clinical study
You may not be if
Patients judged by the investigator(s) to have ILD (provisional cases) among those registered in the cohort OR Randomly selected patients without ILD (controls) for each provisional case
Case-control study: Patients enrolled in the case-control study; all consenting patients with ILD as cases and approximately 4 times as many consenting patients without ILD as controls randomly selected from the cohort
